News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Rehabilitation in primary and metastatic brain tumours : Impact of functional outcomes on survival.


Posted on: 06/04/2008

J Neurol. 2008 May 30; [Epub ahead of print] Related Articles


Rehabilitation in primary and metastatic brain tumours : Impact of functional outcomes on survival.

Tang V, Rathbone M, Park Dorsay J, Jiang S, Harvey D.

Division of Neurology, McMaster University, Hamilton, Canada.

OBJECTIVE : Patients with brain tumours have major disabilities and guarded prognosis but may benefit from inpatient rehabilitation. The objectives were to compare functional outcomes in patients with glioblastoma multiforme (GBM), brain metastases and other brain tumours, and to determine predictors of survival. METHODS : Demographic, clinical, functional, and survival data were collected for 63 patients.Kaplan-Meier and Cox regression were used for survival analyses. RESULTS : Functional Independence Measure (FIMtrade mark) scores improved from admission to discharge for patients with GBM, brain metastases and other tumours. Estimated median survival was 141 days for brain metastases, 214 days for GBM and 439 days for other tumours. Low admission dexamethasone dose and high FIMtrade mark gain predicted better survival in GBM. For brain metastases, high FIMtrade mark gain, low dexamethasone dose and no organ metastases were positive prognostic factors. CONCLUSIONS : Patients with primary and metastatic brain tumours achieved functional gains after rehabilitation. High functional improvement is a significant predictor of longer survival in brain metastases and GBM. This study has implications for rehabilitation in the post-acute management of patients who have disabilities due to brain tumours.

PMID: 18500499 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740